SCHEMBL4287579

SCHEMBL4287579

Cc1nc(Nc2ccc3cn[nH]c3c2)cc(-c2cc(Cl)ccc2C)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGPAT2 O15120 11/20 0.62
DYRK1A Q13627 2/20 0.49
NOS1 P29475 1/20 0.49
EIF2AK2 P19525 1/20 0.48
MAPT P10636 5/20 0.47
TP53 P04637 1/20 0.47
KDM4E B2RXH2 4/20 0.46
KMT2A Q03164 4/20 0.46
ALDH1A1 P00352 3/20 0.46
MEN1 O00255 3/20 0.46
GAA P10253 2/20 0.46
NPC1 O15118 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
RAB9A P51151 1/20 0.46
MCL1 Q07820 1/20 0.46
ATM Q13315 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
MAP4K4 O95819 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13880181 0.89 AGPAT2 (0.78) AGPAT2DYRK1ANOS1EIF2AK2NPC1
SCHEMBL4282928 0.88 AGPAT2 (0.80) AGPAT2MAPTKDM4EKMT2AALDH1A1
SCHEMBL25039650 0.83 AGPAT2 (0.53) AGPAT2MAPTTP53POLB
SCHEMBL4288850 0.81 AGPAT2 (0.74) AGPAT2MAPTTP53NPC1RAB9A
SCHEMBL4363367 0.81 AGPAT2 (0.53) AGPAT2DYRK1ANOS1MAPTKDM4E
SCHEMBL13880166 0.79 AGPAT2 (0.76) AGPAT2DYRK1ANOS1EIF2AK2
SCHEMBL4279343 0.77 AGPAT2 (0.77) AGPAT2MAPTTP53POLB
SCHEMBL13880150 0.77 AGPAT2 (1.00) AGPAT2MAPT
SCHEMBL4366686 0.76 AGPAT2 (0.53) AGPAT2DYRK1ANOS1EIF2AK2MAPT
SCHEMBL4362554 0.75 AGPAT2 (0.64) AGPAT2DYRK1ANOS1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US claimed
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES GERO PTE. LTD. (SG) 2023-02-16 US disclosed
WO-2020080979-A1 PFKFB3 INHIBITORS AND THEIR USES GERO DISCOVERY LIMITED LIABILITY COMPANY (RU) 2020-04-23 WO disclosed
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-20090099183-A1 PYRIMIDINES AND USES THEREOF CELL THERAPEUTICS, INC. (US) 2009-04-16 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-7419984-B2 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. (US) 2008-09-02 US disclosed
US-20040204386-A1 Pyrimidines and uses thereof CELL THERAPEUTICS, INC. 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040204386-A1 Pyrimidines and uses thereof LPCAT3, LPCAT1, APRT AGPAT2 100/4885DYRK1A 3387/4885NOS1 4804/4885
US-20230047816-A1 PFKFB3 INHIBITORS AND THEIR USES PFKFB3, PFKFB4, PFKFB1 AGPAT2 929/4885DYRK1A 2727/4885NOS1 2411/4885
US-20090099183-A1 PYRIMIDINES AND USES THEREOF LPCAT3, LPCAT1, APRT AGPAT2 94/4885DYRK1A 3651/4885NOS1 4763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.